98%
921
2 minutes
20
Background Antidepressant use is increasing during pregnancy but estimates of prevalence and patterns of prescribing are outdated. Aim To describe the prevalence and patterns of antidepressant prescribing in and around pregnancy. Design and setting Drug utilisation study in the UK's Clinical Practice Research Datalink (CPRD) GOLD Pregnancy Register. Methods Using primary care prescription records, we identified individuals who had been prescribed antidepressants in and around pregnancy between 1996-2018 and described prevalence of prescribing during pregnancy over time. We defined 'prevalent' or 'incident' antidepressant prescribed, where 'prevalent' individuals were prescribed antidepressants both before and during pregnancy, and 'incident' individuals were newly prescribed antidepressants during pregnancy, then qualitatively compared patterns of prescribing between these two groups. We also investigated post-pregnancy prescribing, as well as characteristics associated with antidepressant discontinuation anytime during pregnancy. Results A total of 1,033,783 pregnancies were eligible: 79,144 (7.7%) were prescribed antidepressants during pregnancy and 15,733 of these (19.9%) were 'incident'. Antidepressant prescribing during pregnancy increased from 3.2% in 1996 to 13.4% in 2018. Most women, both 'prevalent' and 'incident' prescribed, discontinued antidepressants anytime during pregnancy (54.8% and 59.9%, respectively). Over half of those who discontinued during pregnancy were prescribed antidepressants in the 12 months after pregnancy (53.0%). Younger age, previous stillbirth, and higher deprivation were associated with more frequent discontinuation anytime during pregnancy. Conclusions Antidepressant prescribing during pregnancy has been increasing in the UK. Over half of the sample discontinued antidepressants at some point before the end of pregnancy, but post-pregnancy resumption of antidepressants was common.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3399/BJGP.2025.1093 | DOI Listing |
Front Pharmacol
August 2025
Department of Education and Support for Regional Medicine (General and Kampo Medicine), Tohoku University Hospital, Sendai, Japan.
Introduction: Traditional Japanese (Kampo) medicine containing kernel (KPK) is prescribed for treating menstrual- and pregnancy-related symptoms. However, no safety information is available regarding its use in pregnant women. In this study, we examined the associations of KPK prescriptions during the first trimester of pregnancy with preterm births and major congenital malformations (MCMs) in newborns.
View Article and Find Full Text PDFBr J Psychiatry
September 2025
Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Background: Although current prescribing guidelines suggest continuation of psychotropic drugs in pregnant women, population-based evidence supporting their safety is limited.
Aims: This study aims to clarify the plausible causal links between maternal psychotropic drug exposures and obstetric complications.
Method: This cohort study investigated all births by Hong Kong residents ≥18 years of age in public hospitals between 2004 and 2022.
ACS Omega
August 2025
Koret School of Veterinary Medicine, The RH Smith Faculty of Agriculture, Food and Environmental Sciences, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
The anticonvulsant drug carbamazepine is ubiquitous in the environment and has even even detected in human urine after consuming produce irrigated with reclaimed wastewater. Whether unintentional carbamazepine exposure through food and water affects public health is unknown. Its potential adverse effects are particularly concerning during pregnancy, as carbamazepine increases the risk of intrauterine growth restriction and congenital malformations in fetuses of carbamazepine-prescribed mothers.
View Article and Find Full Text PDFObjective: To examine longitudinal changes in the initial prescribing of glucagon-like peptide 1 (GLP-1) receptor agonists for women of reproductive age in Australia; to determine whether contraception recommendations are being followed; and to estimate the frequency of pregnancy among women using GLP-1 receptor agonists.
Study Design: Retrospective open cohort study; analysis of MedicineInsight general practice data.
Setting, Participants: Women aged 18-49 years who visited participating general practices three or more times during the study period (1 January 2011 - 31 July 2022).